AAP
MDGL icon

Arax Advisory Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Arax Advisory Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27
Closed -$15.7K – 4122
2025
Q4 		$15.7K Buy
27
+12
+80% +$6.13K ﹤0.01% 2245
2025
Q3 		$6.88K Buy
+15
New +$5.6K ﹤0.01% 2759

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's MDGL Position: Q1 2026 in Review

Arax Advisory Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 27 shares — an estimated $15.7K sold.

Arax Advisory Partners first reported a position in MDGL in Q3 2025 and held it in 2 quarters. The position peaked at $15.7K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Arax Advisory Partners reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 27 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $15.7K.
  • Arax Advisory Partners first reported a position in Madrigal Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Madrigal Pharmaceuticals position peaked at $15.7K in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.